---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-25-001264"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:34.849620+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance

## Summary
- Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.
- Net loss $17.0M vs $15.5M; diluted EPS $(0.15) vs $(0.17); Adjusted EBITDA $(4.1)M vs $(8.7)M.
- Pharmacy revenue $62.6M with >$11M gross profit; over 40% YoY growth.
- Expanding capitated partnership with Elevance into two new Florida counties (more than double lives) and with Silver Summit in Nevada.
- Reaffirms full-year 2025 guidance; expects revenue at high end of range and positive Adjusted EBITDA by year-end.

## SEC filing metadata
- accession: 0001079973-25-001264
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000107997325001264/0001079973-25-001264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000107997325001264/toi_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-25-001264
- JSON: https://secwatch.observer/filing/0001079973-25-001264.json
- Plain text: https://secwatch.observer/filing/0001079973-25-001264.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.